Shares of HCA Holdings Inc (NYSE:HCA) ended Wednesday session in red amid volatile trading. The shares closed down -1.03 points or -1.35% at $75.13 with 4.02 million shares getting traded. Post opening the session at $76.02, the shares hit an intraday low of $74.05 and an intraday high of $76.02 and the price vacillated in this range throughout the day. The company has a market cap of $28.12 billion and the numbers of outstanding shares have been calculated to be 378.65 million shares.
HCA Holdings Inc (HCA) on September 7, 2016 announced the signing of an agreement to purchase Mobile Heartbeat, a leading developer of applications for smartphones to improve clinical workflow and team communications. Mobile Heartbeat technology solutions consolidate clinical communications, including alarms and notifications, patient information and lab data, secure texting, voice and photography.
HCA recently completed a successful pilot of Mobile Heartbeat’s CURE™ (Clinical Urgent Response) technology for its iMobile Project, an initiative to implement smartphone-based critical care team communications. HCA is launching Mobile Heartbeat’s CURE technology in 21 hospitals across the country with plans to implement the technology enterprise-wide.
“Mobile Heartbeat is an innovator that is keenly focused on meeting the mobile technology needs of clinicians,” said Dr. Jonathan Perlin, HCA’s chief medical officer and president of the Clinical Services Group. “This acquisition will enhance our ability to work closely with Mobile Heartbeat as we continue to create and refine technology solutions to improve clinical workflows and provide secure communications that foster better patient care.”
Following the completion of the transaction, Mobile Heartbeat’s current chief executive officer Ron Remy will serve as CEO of the organization which will operate as an indirect, wholly owned subsidiary of HCA. Mobile Heartbeat’s team will continue to serve the company’s clients and market its products to leading healthcare organizations from the company’s location in Massachusetts.
“We’ve worked closely with HCA for several years to better understand the challenges clinicians face and to enhance our applications to meet their needs,” said Remy. “Joining HCA will help us serve our current and future customers through a closer collaboration with one of the leading healthcare providers in the world. HCA’s leadership will be instrumental as we continue to develop improved solutions for secure clinical communications.”
Shares of Celgene Corporation (NASDAQ:CELG) ended Wednesday session in green amid volatile trading. The shares closed up +1.53 points or 1.46% at $106.06 with 4.00 million shares getting traded. Post opening the session at $104.77, the shares hit an intraday low of $104.65 and an intraday high of $106.56 and the price vacillated in this range throughout the day. The company has a market cap of $80.42 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
Celgene Corporation (CELG) on September 12, 2016 announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohn’s disease.
The trial, CD-001, is an ongoing study evaluating three different treatment regimens of GED-0301 in a 12-week treatment phase, followed by an observation phase up to 52 weeks (off treatment). The primary objective of the study is to explore the effect of GED-0301 on endoscopic outcomes. The trial enrolled a total of 63 patients across multiple countries.
The study was designed to further enhance the understanding of GED-0301 activity in a difficult-to-treat, moderate-to-severe patient population. This population was more diverse than prior GED-0301 studies and included patients with endoscopically confirmed mucosal damage at entry and those who had previous surgeries. The study also included both biologic exposed and biologic naïve patients as well as patients with a diagnosis of Ileitis, Ileocolitis or colitis.
Topline data from CD-001 show that in a proportion of patients treated with oral GED-0301 there was endoscopic improvement (defined as a 25 percent improvement from baseline) and clinical response and remission across all treatment groups at week 12. Findings to date reveal no new safety signals and tolerability is consistent with earlier studies.
“Given the high unmet need in Crohn’s disease, we are pleased that oral GED-0301 showed both endoscopic improvements and clinically meaningful responses and remission at an early timepoint in this study,” said Scott Smith, President of Celgene Inflammation and Immunology. “These data are particularly encouraging for several reasons, including the difficult-to-treat patient population evaluated in the trial.”